source
- STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fightA top Republican is asking if the AMA's codes are helping to fuel health care fraud.
- Intercept’s next-generation FXR agonist INT-787 fails Phase 2 trial in alcohol-associated hepatitisIntercept Pharmaceuticals reported that its experimental FXR agonist INT-787 did not demonstrate efficacy in a Phase 2 study of patients with severe alcohol-associated hepatitis. The trial results…